Fierce Pharma5d
FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again
Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
BioSpace8d
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...
CURE6d
Golidocitinib Plus PD-1 Antibodies Being Explored in Lung Cancer Subset
Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...
Cure Today23d
FDA Approves Tevimbra Plus Chemotherapy For Some With Esophageal Cancer
Tevimbra is a monoclonal antibody and immune checkpoint inhibitor targeting PD-1 on T cells, enhancing immune-mediated cancer cell destruction ... 39.9 months based on response characteristics. The ...
CNBCTV189d
Shilpa Medicare arm partners with Switzerland-based mAbTree Biologics for new cancer drug
While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...
Healio9d
Two-drug regimen active in advanced endometrial cancer
A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...
Benzinga.com22d
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
FDA approved Tevimbra plus chemo for first-line ... esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). The additional indication is based on results from the RATIONALE ...
pharmaphorum7d
FDA won't back Lilly's PD-1 antibody based on Chinese data alone
The FDA has dropped a bomb on Eli Lilly's marketing application for cancer immunotherapy sintilimab ... clinical results filed in support of the PD-1 inhibitor do not meet the criteria for foreign ...
pharmaphorum12d
Merck gets FDA okay for Keytruda as liver cancer therapy
Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda ... form of liver cancer, opening up another front in its rivalry with Bristol-Myers Squibb. The FDA approval is based on ...
manilatimes8d
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer
Receiving an Orphan Drug Designation for HLX22 recognizes its potential ... and immune checkpoint inhibitors (anti-PD-1/PD-L1 mAbs) for gastric cancer treatment in recent years, the disease's high ...